LUCIUS 卢修斯 阿西替尼 Axitinib晚期肾细胞癌

阿西替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Axitinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:

Each film-coated tablet contains

晚期肾细胞癌

Axitinib ......

LUCIUS

Indieation:

... 5mg.

PHARMACEUTICALS

LuciAxi is a kinase inhibitor indicated for
the treatment of advanced renal cell
carcinoma after failure of one prio
svetamie therapy.
Dosageand Use:
The starting dose 1s 3 mg orally twice

LUCIAXI

dally. Dose adjustments can be made base
on individual safety and tolerability.
. Administer LuciAxI dose approximately

FDA批准

12 hours apart with or without food.

Axitinib Tablets

e approximatel
Storage: in a dry place and store at 20Cto

5mg

25C

Warning:

Keep medicine out of reach of Children. Do
not administer LuciAxi during Pregnancy

Rx Only

and Lactation.
PLEASESEEPACKAGE INSERT
Manufactured and Marketed by:

LUCIUS

权威认证

PHARMACEUTICALS
Thongmang village, Xaythany distri

Vientiane Capital. Laos

www.lucius.la
Warning : 1o be sold by retail on nrecere
ol registered physicians only, and as directed

60 Tablets

口碑质量

适应症:
用于治疗先前一种全身疗法失败后的晚期肾细胞癌。
推荐剂量:
1、起始剂量为每日口服两次,每次5毫克。可根据个人安
全性和耐受性调整剂量。
2、每次间隔约12小时,可与食物同附或单独服用。
3、如果需要联合使用强效CYP3A4/5抑制剂,则将阿西
替尼的剂量减少一半。
4、对于中度肝功能不全的患者,将起始剂量减少一半。